GENMAB AS SP.ADR/1/10DK 1 (GE91) - Total Liabilities

Latest as of December 2025: €7.03 Billion EUR ≈ $8.21 Billion USD

Based on the latest financial reports, GENMAB AS SP.ADR/1/10DK 1 (GE91) has total liabilities worth €7.03 Billion EUR (≈ $8.21 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore GE91 year-over-year net asset growth to track the company's year-over-year net asset growth rate.

GENMAB AS SP.ADR/1/10DK 1 - Total Liabilities Trend (2021–2025)

This chart illustrates how GENMAB AS SP.ADR/1/10DK 1's total liabilities have evolved over time, based on quarterly financial data.

GENMAB AS SP.ADR/1/10DK 1 Competitors by Total Liabilities

The table below lists competitors of GENMAB AS SP.ADR/1/10DK 1 ranked by their total liabilities.

Company	Country	Total Liabilities
HAIER SM.HME UNSP.ADR/4 F:HAI0	Germany	€165.78 Billion
Bank of Baroda NSE:BANKBARODA	India	Rs18.06 Trillion
Yunnan Aluminium Co Ltd SHE:000807	China	CN¥11.08 Billion
Banco Santander Chile SN:BSANTANDER	Chile	CL$65.00 Trillion
Banco de Chile F:G4RA	Germany	€49.93 Trillion
Ball Corporation NYSE:BALL	USA	$14.15 Billion
Formosa Petrochemical Corp TW:6505	Taiwan	NT$63.81 Billion
Mueller Industries Inc NYSE:MLI	USA	$581.53 Million

Liability Composition Analysis (2021–2025)

This chart breaks down GENMAB AS SP.ADR/1/10DK 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of GENMAB AS SP.ADR/1/10DK 1.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.02	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.20	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.55	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how GENMAB AS SP.ADR/1/10DK 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)

The table below shows the annual total liabilities of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025.

Year	Total Liabilities	Change
2025-12-31	€7.03 Billion ≈ $8.21 Billion	+452.55%
2024-12-31	€1.27 Billion ≈ $1.49 Billion	+132.79%
2023-12-31	€546.23 Million ≈ $638.60 Million	+33.77%
2022-12-31	€408.32 Million ≈ $477.37 Million	+10.33%
2021-12-31	€370.09 Million ≈ $432.67 Million	--

About GENMAB AS SP.ADR/1/10DK 1

F:GE91 Germany Biotechnology

Market Cap

$17.14 Billion

€14.66 Billion EUR

Market Cap Rank

#1631 Global

#351 in Germany

Share Price

€23.80

Change (1 day)

+3.48%

52-Week Range

€17.00 - €29.80

All Time High

€44.40